

David W Mudge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4364880/publications.pdf>

Version: 2024-02-01

80
papers

5,361
citations

147801

31
h-index

82547

72
g-index

80
all docs

80
docs citations

80
times ranked

6164
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet</i> , The, 2011, 377, 2181-2192. | 13.7 | 2,087 |
| 2 | Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis. <i>New England Journal of Medicine</i> , 2014, 370, 13-22. | 27.0 | 804 |
| 3 | Randomized, Controlled Trial of Topical Exit-Site Application of Honey (Medihoney) versus Mupirocin for the Prevention of Catheter-Associated Infections in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1456-1462. | 6.1 | 135 |
| 4 | Predictors of Decline of Residual Renal Function in New Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 276-283. | 2.3 | 130 |
| 5 | Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Access Trial (NEAT). <i>American Journal of Kidney Diseases</i> , 2017, 70, 486-497. | 1.9 | 115 |
| 6 | Free Mycophenolic Acid Should Be Monitored in Renal Transplant Recipients with Hypoalbuminemia. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 284-286. | 2.0 | 108 |
| 7 | Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. <i>Nephrology</i> , 2007, 12, 391-398. | 1.6 | 102 |
| 8 | Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 271-280. | 2.4 | 97 |
| 9 | Altered dietary salt intake for people with chronic kidney disease. <i>The Cochrane Library</i> , 2015, , CD010070. | 2.8 | 96 |
| 10 | Peritoneal dialysis practice in Australia and New Zealand: A call to action. <i>Nephrology</i> , 2011, 16, 19-29. | 1.6 | 74 |
| 11 | A Randomized Controlled Trial of Coiled Versus Straight Swan-Neck Tenckhoff Catheters in Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2006, 48, 812-821. | 1.9 | 71 |
| 12 | Automated and continuous ambulatory peritoneal dialysis have similar outcomes. <i>Kidney International</i> , 2008, 73, 480-488. | 5.2 | 68 |
| 13 | The impact of automated eGFR reporting and education on nephrology service referrals. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3845-3850. | 0.7 | 68 |
| 14 | Predictors of decline of residual renal function in new peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 276-83. | 2.3 | 66 |
| 15 | Intradermal Versus Intramuscular Hepatitis B Vaccination in Hemodialysis Patients: A Prospective Open-Label Randomized Controlled Trial in Nonresponders to Primary Vaccination. <i>American Journal of Kidney Diseases</i> , 2009, 54, 95-103. | 1.9 | 63 |
| 16 | The impact of extendedâ€”hours home hemodialysis and buttonhole cannulation technique on hospitalization rates for septic events related to dialysis access. <i>Hemodialysis International</i> , 2010, 14, 451-463. | 0.9 | 61 |
| 17 | Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid-chromatography using mass spectrometric and ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 799, 157-163. | 2.3 | 54 |
| 18 | Phosphate binders in patients with chronic kidney disease. <i>Australian Prescriber</i> , 2017, 40, 9-14. | 1.0 | 54 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Severe Toxicity Associated with a Markedly Elevated Mycophenolic Acid Free Fraction in a Renal Transplant Recipient. Therapeutic Drug Monitoring, 2004, 26, 453-455. | 2.0 | 48 |
| 20 | Achieving Salt Restriction in Chronic Kidney Disease. International Journal of Nephrology, 2012, 2012, 1-10. | 1.3 | 43 |
| 21 | Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?. BMC Nephrology, 2011, 12, 20. | 1.8 | 42 |
| 22 | Changes in serum prolactin, sex hormones and thyroid function with alternate nightly nocturnal home haemodialysis. Nephrology, 2012, 17, 42-47. | 1.6 | 42 |
| 23 | Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. Nephrology Dialysis Transplantation, 2006, 21, 776-783. | 0.7 | 41 |
| 24 | Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. The Cochrane Library, 2017, 2017, CD004679. | 2.8 | 41 |
| 25 | The effect of oral iron administration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. Transplantation, 2004, 77, 206-209. | 1.0 | 40 |
| 26 | Quality of life and alternate nightly nocturnal home hemodialysis. Hemodialysis International, 2010, 14, 29-38. | 0.9 | 39 |
| 27 | Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. Nephrology Dialysis Transplantation, 2017, 32, 1530-1539. | 0.7 | 38 |
| 28 | Prevention of peritoneal dialysis-related infections. Nephrology Dialysis Transplantation, 2015, 30, 1461-1472. | 0.7 | 37 |
| 29 | A Comparison of Peritoneal Equilibration Tests Performed 1 and 4 Weeks after PD Commencement. Peritoneal Dialysis International, 2004, 24, 460-465. | 2.3 | 36 |
| 30 | Cutaneous manifestations of cytomegalovirus disease in renal transplant recipients: a case series. Transplant Infectious Disease, 2008, 10, 209-213. | 1.7 | 36 |
| 31 | Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. Nephrology, 2007, 12, 224-233. | 1.6 | 35 |
| 32 | A Randomized Controlled Trial of Intravenous or Oral Iron for Posttransplant Anemia in Kidney Transplantation. Transplantation, 2012, 93, 822-826. | 1.0 | 33 |
| 33 | A Randomized Controlled Trial of Fludrocortisone for the Treatment of Hyperkalemia in Hemodialysis Patients. American Journal of Kidney Diseases, 2006, 47, 809-814. | 1.9 | 30 |
| 34 | Altered dietary salt intake for people with chronic kidney disease. The Cochrane Library, 2021, 2021, CD010070. | 2.8 | 30 |
| 35 | Estimated donor glomerular filtration rate is the most important donor characteristic predicting graft function in recipients of kidneys from live donors. Transplant International, 2007, 20, 64-72. | 1.6 | 29 |
| 36 | Peritoneal dialysis practice in Australia and New Zealand: A call to sustain the action. Nephrology, 2016, 21, 535-546. | 1.6 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Patientsâ€™ Perspectives on the Prevention and Treatment of Peritonitis in Peritoneal Dialysis: A Semi-Structured Interview Study. Peritoneal Dialysis International, 2016, 36, 631-639. | 2.3 | 28 |
| 38 | Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. BMC Nephrology, 2017, 18, 281. | 1.8 | 25 |
| 39 | A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOcrit trial. Nephrology Dialysis Transplantation, 2012, 27, 4146-4153. | 0.7 | 24 |
| 40 | Coca-Cola and kangaroos. Lancet, The, 2004, 364, 1190. | 13.7 | 19 |
| 41 | The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis. Peritoneal Dialysis International, 2015, 35, 222-228. | 2.3 | 19 |
| 42 | HumanSLC26A1 Gene Variants: A Pilot Study. Scientific World Journal, The, 2013, 2013, 1-7. | 2.1 | 18 |
| 43 | Rationale and design of the HEALTHY-CATH trial: A randomised controlled trial of Heparin versus Ethanol Lock Therapy for the prevention of Catheter Associated infection in Haemodialysis patients. BMC Nephrology, 2009, 10, 23. | 1.8 | 17 |
| 44 | <sc>KHAâ€™CARL</sc> Guideline: Peritonitis treatment and prophylaxis. Nephrology, 2014, 19, 69-71. | 1.6 | 17 |
| 45 | Assessment of current practice and barriers to antimicrobial prophylaxis in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2016, 31, 619-627. | 0.7 | 17 |
| 46 | Paracetamol and asthma. Thorax, 2000, 55, 882-882. | 5.6 | 16 |
| 47 | Induction and maintenance therapy in ANCAâ€™associated systemic vasculitis. Nephrology, 2008, 13, S24-36. | 1.6 | 16 |
| 48 | Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. BMC Nephrology, 2009, 10, 29. | 1.8 | 16 |
| 49 | A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Research and Therapy, 2014, 11, 35. | 1.7 | 16 |
| 50 | Deceased donor renal transplantationâ€™ does side matter?. Nephrology Dialysis Transplantation, 2006, 21, 2583-2588. | 0.7 | 15 |
| 51 | Pharmacokinetics and normal scintigraphic appearance of 99mTc aprotinin. Nuclear Medicine Communications, 2005, 26, 535-539. | 1.1 | 14 |
| 52 | Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2017, 37, 397-406. | 2.3 | 14 |
| 53 | Methamphetamine intoxication and acute kidney injury: A prospective observational case series. Nephrology, 2020, 25, 758-764. | 1.6 | 14 |
| 54 | Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance. Nephrology Dialysis Transplantation, 2005, 20, 2178-2185. | 0.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Intravenous versus oral iron supplementation for correction of post-transplant anaemia in renal transplant patients. BMC Nephrology, 2009, 10, 14. | 1.8 | 11 |
| 56 | Hepatic vein stenting for recurrent ascites in polycystic liver and kidney disease. Nephrology Dialysis Transplantation, 2005, 20, 2566-2568. | 0.7 | 10 |
| 57 | Life-threatening adenovirus infection in a kidney transplant recipient. CKJ: Clinical Kidney Journal, 2009, 2, 250-253. | 2.9 | 10 |
| 58 | Cardiac and vascular structure and function parameters do not improve with alternate nightly home hemodialysis: An interventional cohort study. BMC Nephrology, 2011, 12, 51. | 1.8 | 10 |
| 59 | Change in live donor characteristics over the last 25 years: A single centre experience. Nephrology, 2008, 13, 646-650. | 1.6 | 9 |
| 60 | Rationale and design of the oral HEME iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 | 0.8 | 10 |
| 61 | Effect of FX Dialysers on Systemic Inflammation and Quality of Life in Chronic Haemodialysis Patients. Blood Purification, 2009, 27, 187-193. | 1.8 | 8 |
| 62 | Infection Prophylaxis in Peritoneal Dialysis Patients: Results from an Australia/New Zealand Survey. Peritoneal Dialysis International, 2017, 37, 191-197. | 2.3 | 7 |
| 63 | Hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis presenting with a vasculitic syndrome, acute nephritis and a puzzling skin rash: a case report. Journal of Medical Case Reports, 2013, 7, 20. | 0.8 | 6 |
| 64 | Pro: Meta-analysis: the case<i>for</i>. Nephrology Dialysis Transplantation, 2016, 31, 875-880. | 0.7 | 6 |
| 65 | Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry. Nephrology, 2020, 25, 683-690. | 1.6 | 6 |
| 66 | Iron Therapy in Renal Transplant Recipients. Transplantation, 2004, 78, 1239-1240. | 1.0 | 5 |
| 67 | Altered dietary salt intake for chronic kidney disease. , 2012, , . | | 5 |
| 68 | Avoiding or stopping steroids in kidney transplant recipients: sounds good but does it work?. , 2016, 8, ED000114. | | 4 |
| 69 | Probable tacrolimus toxicity from tibolone co-administration in a woman: a case report. Journal of Medical Case Reports, 2010, 4, 276. | 0.8 | 3 |
| 70 | Pancreatic and biliary obstruction years after retention of a swallowed coin in a duodenal diverticulum: a case report. Journal of Medical Case Reports, 2015, 9, 144. | 0.8 | 3 |
| 71 | Temporal Changes in Deceased Kidney Donor Characteristics in Australia. Transplantation Direct, 2016, 2, e112. | 1.6 | 3 |
| 72 | Obliterative bronchiolitis or opportunistic infection? A diagnostic challenge in a renal transplant patient. Nephrology Dialysis Transplantation, 2005, 20, 246-247. | 0.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | DABIGATRAN MAY NOT BE AN EFFECTIVE ANTICOAGULANT FOR HAEMODIALYSIS. Nephrology, 2010, 15, 594-595. | 1.6 | 2 |
| 74 | Kidney transplantation without reversal of warfarin. CKJ: Clinical Kidney Journal, 2010, 3, 170-171. | 2.9 | 1 |
| 75 | Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, 885-886. | 0.7 | 1 |
| 76 | Recurrent atypical haemolytic uraemic syndrome post kidney transplant due to aCD46mutation in the setting ofSMARCAL1-mediated inherited kidney disease. Nephrology, 2017, 22, 11-14. | 1.6 | 1 |
| 77 | Tacrolimus Toxicity due to Biliary Obstruction in a Combined Kidney and Liver Transplant Recipient. Case Reports in Transplantation, 2017, 2017, 1-4. | 0.3 | 1 |
| 78 | Response: Iron Therapy in Renal Transplant Recipients. Transplantation, 2004, 78, 1240. | 1.0 | 0 |
| 79 | Interventions for post-transplant anaemia in kidney transplant recipients. The Cochrane Library, 0, , . | 2.8 | 0 |
| 80 | Utility of "back-to-back" arteriovenous fistulae in patients on peritoneal dialysis and use of haemodialysis catheters. Internal Medicine Journal, 2020, 51, 1106-1110. | 0.8 | 0 |